Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease - PubMed (original) (raw)
Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease
Christopher B Forsyth et al. PLoS One. 2011.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder of aging. The pathological hallmark of PD is neuronal inclusions termed Lewy bodies whose main component is alpha-synuclein protein. The finding of these Lewy bodies in the intestinal enteric nerves led to the hypothesis that the intestine might be an early site of PD disease in response to an environmental toxin or pathogen. One potential mechanism for environmental toxin(s) and proinflammatory luminal products to gain access to mucosal neuronal tissue and promote oxidative stress is compromised intestinal barrier integrity. However, the role of intestinal permeability in PD has never been tested. We hypothesized that PD subjects might exhibit increased intestinal permeability to proinflammatory bacterial products in the intestine. To test our hypothesis we evaluated intestinal permeability in subjects newly diagnosed with PD and compared their values to healthy subjects. In addition, we obtained intestinal biopsies from both groups and used immunohistochemistry to assess bacterial translocation, nitrotyrosine (oxidative stress), and alpha-synuclein. We also evaluated serum markers of endotoxin exposure including LPS binding protein (LBP). Our data show that our PD subjects exhibit significantly greater intestinal permeability (gut leakiness) than controls. In addition, this intestinal hyperpermeability significantly correlated with increased intestinal mucosa staining for E. coli bacteria, nitrotyrosine, and alpha-synuclein as well as serum LBP levels in PD subjects. These data represent not only the first demonstration of abnormal intestinal permeability in PD subjects but also the first correlation of increased intestinal permeability in PD with intestinal alpha-synuclein (the hallmark of PD), as well as staining for gram negative bacteria and tissue oxidative stress. Our study may thus shed new light on PD pathogenesis as well as provide a new method for earlier diagnosis of PD and suggests potential therapeutic targets in PD subjects.
Trial registration: Clinicaltrials.gov NCT01155492.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Figure 1. Consort 2010 flow diagram of this study.
12 research subjects were invited to participate in this study. Two were excluded because they failed to meet inclusion criteria (prohibited medications). One study subject incorrectly performed the 24-hour urine collection for intestinal permeability testing and his data were excluded from analysis. Nine study subjects completed all study assessments.
Figure 2. Intestinal permeability to lactulose and mannitol is similar in control and PD subjects.
PD subjects and healthy controls were assessed for intestinal permeability using an oral sugar solution containing sucrose, lactulose, mannitol, and sucralose and GC analysis of 24 hour urine samples as described in Materials and Methods. Urinary lactulose and mannitol as well as the L/M ratio (all primarily measures of small intestinal permeability) were not significantly different in PD patients compared to controls. Data are presented as mean % urinary excretion of the oral dose in 24 hours ± SE. * p<0.05.
Figure 3. Intestinal permeability to sucralose is significantly greater in PD patients.
PD subjects and healthy controls were assessed for intestinal permeability using an oral sugar solution containing sucrose, lactulose, mannitol, and sucralose and GC analysis of 24 hour urine samples as described in Materials and Methods. Urinary sucralose, a measure of whole intestine permeability, was significantly greater in PD subjects vs. healthy age matched controls. Data are presented as mean % urinary excretion of the oral dose in 24 hours ± SE. * p<0.05.
Figure 4. Plasma LBP is significantly lower in PD patients.
Plasma levels of LPS binding protein (LBP), an indirect measure of systemic endotoxin exposure, were determined for PD subjects and healthy controls as described in Materials and Methods. Values for plasma LBP in PD subjects were significantly lower than in healthy controls. Data are presented as means (ng/ml) ± SE. *p<0.05.
Figure 5. Immunohistochemical staining of intestinal biopsies for E. coli, α-synuclein, and 3-NT is significantly greater in PD subjects.
Intestinal biopsies from PD subjects and healthy controls were formalin fixed, paraffin embedded, and then cut to 5 µm and processed as described in Materials and Methods for each respective antibody to either E.coli gram negative bacteria (A,D,G), α-synuclein (B,E,H) or 3-nitrotyrosine (3-NT)(C,F,I). Representative images are shown from a PD subject at 15× (A–C) and 40× (D–F) magnification using the same field of view and from a healthy control subject (G–I) at 40×. Staining data were analyzed by blinded observers and PD subjects were found to stain significantly greater for E. coli, α-synuclein, and 3-NT. Scale bars = A–C 50 µm, D–I 100 µm.
Similar articles
- Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.
Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, Bakay RA, Kordower JH. Kelly LP, et al. Mov Disord. 2014 Jul;29(8):999-1009. doi: 10.1002/mds.25736. Epub 2013 Nov 4. Mov Disord. 2014. PMID: 24898698 Free PMC article. - Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH. Shannon KM, et al. Mov Disord. 2012 May;27(6):709-15. doi: 10.1002/mds.23838. Epub 2011 Jul 15. Mov Disord. 2012. PMID: 21766334 - The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease.
Shi J, Wang Y, Chen D, Xu X, Li W, Li K, He J, Su W, Luo Q. Shi J, et al. Appl Microbiol Biotechnol. 2023 Mar;107(5-6):1917-1929. doi: 10.1007/s00253-023-12410-w. Epub 2023 Feb 16. Appl Microbiol Biotechnol. 2023. PMID: 36795141 Free PMC article. - The Endotoxin Hypothesis of Parkinson's Disease.
Brown GC, Camacho M, Williams-Gray CH. Brown GC, et al. Mov Disord. 2023 Jul;38(7):1143-1155. doi: 10.1002/mds.29432. Epub 2023 May 8. Mov Disord. 2023. PMID: 37157885 Free PMC article. Review. - Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.
Dodiya HB, Forsyth CB, Voigt RM, Engen PA, Patel J, Shaikh M, Green SJ, Naqib A, Roy A, Kordower JH, Pahan K, Shannon KM, Keshavarzian A. Dodiya HB, et al. Neurobiol Dis. 2020 Feb;135:104352. doi: 10.1016/j.nbd.2018.12.012. Epub 2018 Dec 21. Neurobiol Dis. 2020. PMID: 30579705 Review.
Cited by
- Trends and hotspots on the relationship between gut microbiota and Parkinson's Disease: a bibliometric analysis.
Li X, Hao X, Chen C, Zhai C, Pan T, Zhou X, Liu Y, Wu D, Chen X. Li X, et al. Front Cell Infect Microbiol. 2024 Sep 30;14:1421270. doi: 10.3389/fcimb.2024.1421270. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39403202 Free PMC article. Review. - Infections in the Etiology of Parkinson's Disease and Synucleinopathies: A Renewed Perspective, Mechanistic Insights, and Therapeutic Implications.
Mercado G, Kaeufer C, Richter F, Peelaerts W. Mercado G, et al. J Parkinsons Dis. 2024;14(7):1301-1329. doi: 10.3233/JPD-240195. J Parkinsons Dis. 2024. PMID: 39331109 Free PMC article. Review. - Promotion of a Mediterranean Diet Alters Constipation Symptoms and Fecal Calprotectin in People with Parkinson's Disease: A Randomized Controlled Trial.
Rusch C, Beke M, Nieves C Jr, Mai V, Stiep T, Tholanikunnel T, Ramirez-Zamora A, Hess CW, Langkamp-Henken B. Rusch C, et al. Nutrients. 2024 Sep 2;16(17):2946. doi: 10.3390/nu16172946. Nutrients. 2024. PMID: 39275262 Free PMC article. Clinical Trial. - Psychobiotic Properties of Lactiplantibacillus plantarum in Neurodegenerative Diseases.
Di Chiano M, Sallustio F, Fiocco D, Rocchetti MT, Spano G, Pontrelli P, Moschetta A, Gesualdo L, Gadaleta RM, Gallone A. Di Chiano M, et al. Int J Mol Sci. 2024 Aug 31;25(17):9489. doi: 10.3390/ijms25179489. Int J Mol Sci. 2024. PMID: 39273435 Free PMC article. Review. - The role of gut-derived short-chain fatty acids in Parkinson's disease.
Saadh MJ, Mustafa AN, Mustafa MA, S RJ, Dabis HK, Prasad GVS, Mohammad IJ, Adnan A, Idan AH. Saadh MJ, et al. Neurogenetics. 2024 Oct;25(4):307-336. doi: 10.1007/s10048-024-00779-3. Epub 2024 Sep 13. Neurogenetics. 2024. PMID: 39266892 Review.
References
- Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373:2055–2066. - PubMed
- Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384–386. - PubMed
- Hobson P, Meara J, Ishihara-Paul L. The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK population. J Neurol Neurosurg Psychiatry. 2010;81:1093–1098. - PubMed
- Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology. 2008;70:1916–1925. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous